{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:40:25Z","timestamp":1761100825756},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,2,15]],"date-time":"2006-02-15T00:00:00Z","timestamp":1139961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>  <jats:italic>Objectives<\/jats:italic>:\u2002Despite effective preemptive and prophylactic therapeutic strategies, cytomegalovirus (CMV) seropositivity of either recipient and\/or donor still remains an important parameter for outcome even after reduced\u2010intensity allogeneic stem cell transplantation (SCT). Whether CMV seropositivity of the donor might have an impact on leukemic relapse is unknown. <jats:italic>Patients<\/jats:italic>:\u2002Between June 1999 and February 2004 48 patients ineligible for conventional allotransplantation underwent reduced\u2010intensity transplants at our institution. Twenty\u2010seven (56%) patients had a CMV\u2010seropositive donor. <jats:italic>Results<\/jats:italic>:\u2002While donor CMV seropositivity had no effect on overall survival, having a CMV\u2010seropositive donor was associated with a significantly lower risk for relapse (20% vs. 52%, <jats:italic>P<\/jats:italic>\u2003=\u20030.02). The beneficial effect of a CMV\u2010seropositive donor, however, was offset by a higher transplant\u2010related mortality (42% vs. 19% in patients with a CMV\u2010seronegative donor, <jats:italic>P<\/jats:italic>\u2003=\u20030.2). Donor CMV serostatus had no effect on the incidence of CMV infection\/disease, and acute or chronic graft\u2010vs.\u2010host disease. Overall, 27 patients died during the observation period. Causes of death in patients with a CMV\u2010seropositive donor were primarily transplant\u2010related (11 vs. 4 in patients with CMV\u2010seronegative donors), whereas leukemic relapse was the leading cause of death in patients with a CMV\u2010seronegative donor (8 vs. 4 in patients with a CMV\u2010seropositive donor, <jats:italic>P<\/jats:italic>\u2003=\u20030.038, chi\u2010squared test). Multivariate Cox regression analysis showed risk category by the underlying disease and donor CMV seropositivity to be significant predictors of leukemic relapse following reduced\u2010intensity transplants. <jats:italic>Conclusions<\/jats:italic>:\u2002These preliminary results suggest a possible role of donor CMV serostatus on the risk of relapse following reduced\u2010intensity allogeneic SCT.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2005.00625.x","type":"journal-article","created":{"date-parts":[[2006,2,15]],"date-time":"2006-02-15T11:28:55Z","timestamp":1140002935000},"page":"414-419","source":"Crossref","is-referenced-by-count":26,"title":["Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced\u2010intensity transplants"],"prefix":"10.1111","volume":"76","author":[{"given":"David","family":"Nachbaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,2,15]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(03)00287-8"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.3.478"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3616"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3637"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2043"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3263"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/338624"},{"key":"e_1_2_5_9_2","first-page":"413","article-title":"Graft\u2010versus\u2010leukaemia activity associated with CMV\u2010seropositive donor, post\u2010transplant CMV infection, young donor age and chronic graft\u2010versus\u2010host disease in bone marrow allograft recipients","volume":"5","author":"Jacobsen N","year":"1990","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06275-4"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.08.011"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(03)00201-7"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/10245330210000013898"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703118"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/15258160260194884"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3390"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-197410000-00001"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90380-0"},{"key":"e_1_2_5_20_2","first-page":"2055","article-title":"Prolonged fluconazole prophylaxis for fungal infections after marrow transplantation\u2010a prospective, randomized, double\u2010blind study","volume":"96","author":"Marr K","year":"2002","journal-title":"Blood"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01703449"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/339329"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2005.00625.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2005.00625.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T04:23:48Z","timestamp":1696998228000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2005.00625.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,15]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1111\/j.1600-0609.2005.00625.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00625.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,15]]}}}